Chemomab Therapeutics Ltd.: Scipher Medicine Corp discloses a stake of more than 5% (Schedule 13D)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Scipher Medicine Corp disclosed a stake of more than 5% in Chemomab Therapeutics Ltd. via a Schedule 13D filing with the SEC (accession 0001493152-26-051041). The 13D form signals an active, potentially activist position rather than a passive holding, though the filing excerpt did not specify the exact share count or percentage. The disclosure makes Scipher a significant outside shareholder in the clinical-stage biotech, which is developing therapies for fibrotic and inflammatory diseases. Investors will watch for any amendments detailing Scipher's intent—whether strategic, activist, or investment-only—and for subsequent purchases or board-related demands.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Scipher Medicine Corp, Chemomab Therapeutics Ltd.